Monopar Therapeutics Inc.

NASDAQ: MNPR · Real-Time Price · USD
35.87
0.01 (0.03%)
At close: Aug 15, 2025, 3:59 PM
35.71
-0.45%
After-hours: Aug 15, 2025, 04:10 PM EDT

Monopar Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-3.25B -17.66M -16.16M -7M -7.49M -8.03M -8.83M -9.83M -10.17M -10.6M -10.54M -10.31M -10.36M -9.69M -9.13M -8.71M -7.9M -7.27M
Interest Income
781.61M 918.7K 404.02K 353.06K 365.97K 420.72K 429.04K 343.63K 239.06K 111.26K 21.24K 9.1K 1.98K 13.79K 24.02K 33.4K 41.37K 47.46K
Pretax Income
-3.77B -1.32B -1.32B -1.31B -7.12M -7.61M -8.4M -9.48M -9.93M -10.49M -10.52M -10.3M -10.36M -9.68M -9.1M -8.55M -7.73M -7.1M
Net Income
-3.77B -1.32B -1.32B -1.31B -7.12M -7.61M -8.31M -9.38M -9.83M -10.39M -10.5M -10.3M -10.36M -9.68M -9.1M -8.55M -7.73M -7.1M
Selling & General & Admin
1.51B 3.98M 3.16M 2.88M 3.04M 3.12M 3.23M 3.16M 3.09M 3.04M 2.95M 2.84M 2.79M 2.73M 2.63M 2.56M 2.32M 2.34M
Research & Development
1.74B 13.68M 13.01M 4.12M 4.45M 4.91M 5.6M 6.67M 7.08M 7.57M 7.59M 7.47M 7.57M 6.96M 6.49M 6.14M 5.57M 4.93M
Other Expenses
632.00 826.00 -123 -496 -1.07K -1.26K -871 -474 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
3.25B 17.66M 16.16M 7M 7.49M 8.03M 8.83M 9.83M 10.17M 10.6M 10.54M 10.31M 10.36M 9.69M 9.13M 8.71M 7.9M 7.27M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
-590.03M -590.03M -590.03M -590.03M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
15.87M 17.66M 16.16M 7M 7.49M 8.03M 8.83M 9.83M 10.17M 10.6M 10.54M 10.31M 10.36M 9.69M 9.13M 8.71M 7.9M 7.27M
Income Tax Expense
n/a n/a n/a -1.91K -1.91K -1.91K -92.4K -104.03K -104.03K -104.86K -15.3K -2.81K -2.81K -1.98K -1.05K n/a n/a n/a
Shares Outstanding (Basic)
7M 6.91M 37.9M 3.52M 3.5M 15.98M 14.9M 14.12M 13.42M 13.11M 12.95M 12.76M 12.63M 12.6M 12.58M 12.58M 12.57M 12.14M
Shares Outstanding (Diluted)
7M 6.99M 37.9M 3.52M 3.5M 15.98M 14.9M 14.12M 13.42M 13.11M 12.95M 12.76M 12.63M 12.6M 12.58M 12.58M 12.57M 12.14M
EPS (Basic)
-1.39 -1.53 -1.25 -1.08 -0.85 -0.52 -0.6 -0.7 -0.75 -0.81 -0.82 -0.81 -0.82 -0.77 -0.74 -0.72 -0.67 -0.64
EPS (Diluted)
-1.39 -1.53 -1.25 -1.08 -0.85 -0.52 -0.6 -0.7 -0.75 -0.81 -0.82 -0.81 -0.82 -0.77 -0.74 -0.72 -0.67 -0.64
EBITDA
-3.25B -16.23M -14.3M -5.62M -6.43M -7.39M -8.62M -9.72M -10.17M -10.6M -10.54M -10.31M -10.36M -9.69M -9.13M -8.71M -7.9M -7.27M
EBIT
-15.45M -17.17M -15.59M -6.47M -7.12M -7.61M -8.4M -9.48M -9.93M -10.49M -10.52M -10.3M -10.36M -9.68M -9.1M -8.55M -7.73M -7.1M
Depreciation & Amortization
15.87M 17.66M 16.16M 5.09M 3.51M 4.05M 4.85M 7.76M 10.17M 10.6M 10.54M 10.31M 10.36M 9.69M 9.13M 8.71M 7.9M 7.27M